Physician profile
Maria E Ottavi
NPI 1841208766
$2,861.93
in general payments reported to CMS, 2019-2025
28 companies · $457 in 2025
The $457 reported for 2025 was more than what 78% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $663 · 2020: $381 · 2021: $406 · 2022: $333 · 2023: $330 · 2024: $292 · 2025: $457.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,076 · Gift: $3.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,075.70 |
| Gift | $3.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $594.38 | 2019-2023 | |
| Ascend Therapeutics US, LLC | $397.28 | 2020-2024 | |
| Mayne Pharma Commercial LLC | $336.15 | 2021-2025 | |
| Astellas Pharma US INC | $179.31 | 2024-2025 | Veozah |
| Therapeuticsmd, INC. | $172.12 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $153.16 | 2019 | |
| Sage Therapeutics, LLC | $117.72 | 2025 | Zurzuvae |
| Exact Sciences Corporation | $104.44 | 2023-2025 | Cologuard Collection Kit |
| Recordati_rare_diseases_inc. | $103.57 | 2025 | Isturisa |
| Exeltis, USA INC. | $70.71 | 2020-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $66.92 | 2020 | |
| Lupin INC. | $63.72 | 2019-2020 | |
| Eisai INC. | $61.94 | 2020-2021 | |
| Amag Pharmaceuticals, INC. | $45.55 | 2019 | |
| Vertical Pharmaceuticals, LLC | $43.66 | 2019 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Duchesnay USA Incorporated | $42.56 | 2019 | |
| Becton, Dickinson and Company | $38.26 | 2021 | |
| Allergan, INC. | $36.37 | 2020 | |
| Organon LLC | $31.86 | 2024 | |
| Mimedx Group, INC. | $29.61 | 2024 | |
| Sumitomo Pharma America, INC. | $27.06 | 2025 | Myfembree |
| Myovant Sciences INC. | $25.34 | 2022 | |
| Supernus Pharmaceuticals, INC. | $24.46 | 2025 | Qelbree |
| Coopersurgical, INC. | $23.13 | 2019 | |
| Roche Diagnostics Corporation | $20.45 | 2021 | |
| Millicent US INC | $18.29 | 2025 | Femlyv, Intrarosa |
| Convatec INC. | $17.54 | 2019 | |
| Avion Pharmaceuticals | $16.37 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maria Ottavi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.